TUB-040 demonstrated robust clinical activity with a favorable safety profile and excellent tolerability in biomarker-unselected, heavily pre-treated PROC patients At data-cut-off on September 1, 2025 ...
(RTTNews) - Zentalis Pharmaceuticals Inc. (ZNTL) announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with platinum-resistant ovarian cancer or ...
The MarketWatch News Department was not involved in the creation of this content. -- TUB-040 demonstrated robust clinical activity with a favorable safety profile and excellent tolerability in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results